Update: Psilocybe mushrooms cultivation and clinical trials

FOR PUBLIC RELEASE
Groundbreaking collaboration achieves milestones for indigenous Psilocybe
mushrooms cultivation and clinical trial.


18 March 2024


TAIRĀWHITI, New Zealand - Rua Bioscience (NZX:RUA) is pleased to announce a number of exciting
milestones in a health research collaboration focused on the production of indigenous mushrooms
containing the psychoactive psilocybin.


The company has been granted an expanded licence by Manatū Hauora, the NZ Ministry of Health,
to now research all ten indigenous Psilocybe varieties. The cultivation program, led by Rua
Bioscience and local experts, has sourced fungi, established cultivation facilities and sample testing is
now being undertaken at the Institute of Environmental Science and Research (ESR).


A new research agreement has been executed involving eight partners: Rangiwaho Marae, Institute
of Environmental Science & Research (ESR), Manaaki Whenua Landcare Research, the Mātai Medical
Research Institute, Tūranga Health, IO Limited, the New Zealand Drug Foundation and Rua
Bioscience. Other partners are expected to participate in the collaboration as the research
progresses.


Phase I of the marae-based psilocybin clinical trial protocol received full approval from the Health &
Disability Ethics Committees (HDEC), and the Medsafe Standing Committee On Therapeutic Trials
(SCOTT) has granted conditional approval for the trial to proceed.


The Tū Wairua collaboration brings together leading experts and organisations in a concerted effort
to deepen understanding of indigenous varieties of Psilocybe fungi and explore their therapeutic
potential. This collaboration aligns with Rua Bioscience's mission to harness the power of nature to
improve health outcomes and promote well-being.


Paul Naske, CEO of Rua Bioscience, said, "We are incredibly excited to embark on this journey with
our esteemed partners. Through the Tū Wairua collaboration, we aim to investigate the potential of
indigenous Psilocybe varieties to benefit individuals and communities alike. By combining local
knowledge with scientific research, Tū Wairua can pave the way for innovative approaches to health
and wellness with mana whenua leading the process."

Jymal Morgan, General Manager Māori Impact at ESR, expressed his organisation's enthusiasm,
stating, "ESR is proud to be part of the Tū Wairua collaboration, which aligns closely with our
commitment to honouring and supporting Māori communities. ESR is bringing our expertise in
analytical chemistry to Mātauranga Māori to enable innovation."


Jody Toroa, a trustee at Rangiwaho Marae said the marae whānau were pleased to be the conduit
for such an innovative initiative bringing together mātauranga Māori, health researchers and
medicine manufacturing companies. “This is new ground for everyone involved, it’s complex but so
interesting for our whānau and we can’t wait to see whether it might help those we know suffering
from addictions and historical trauma.” Rangiwaho Marae has facilitated access to kaupapa Māori
trainers who will work along psychedelic therapy trainers to prepare a team of kaitieki or guides, to
support participants in each phase of the clinical trial.


Dr. Patrick McHugh, clinical lead at the Mātai Medical Research Institute, highlighted the potential
impact of the collaboration, stating, "Mātai is thrilled to join forces with Rua Bioscience and other
partners in the Tū Wairua collaboration. By combining our expertise in research and technology, we
can unlock new insights into the therapeutic potential of indigenous Psilocybe varieties."


ENDS
The person who authorised this announcement:

Paul Naske
Chief Execu�ve Officer
Paul.naske@ruabio.com

+64 21 445154

For media inquiries, please contact:

Paul Naske - paul.naske@ruabio.com
Manu Caddie - manu@enquire.co.nz

About the participating organisations:

• Rua Bioscience (NZX:RUA) is a leading Aotearoa New Zealand-based biotechnology company
specialising in the research, development, and commercialisation of natural products and
medicinal cannabis products for health and wellness.
• Institute of Environmental Science and Research (ESR) is a Crown Research Institute
dedicated to the health, wellbeing and safety of our communities. Using world-leading
science, we monitor disease, test food and products, safeguard our water, support the
justice sector and more.
• Manaaki Whenua - Landcare Research is a Crown Research Institute that conducts science
and research focused on environmental issues, opportunities and solutions for Aotearoa
New Zealand. This research collaboration has drawn on their expertise in the
identification and cataloguing of indigenous organisms.
• NZ Drug Foundation works to prevent drug harm and build a healthier society.
• The Mātai Medical Research Institute focuses on brain research and technology
development for human health and well-being.

• Tūranga Health is a leading iwi health provider based in Tūranganui-a-Kiwa providing
primary health care and wellbeing services.
• IO Limited is a company focused on research and utilising taonga species in partnership with
kaitiaki groups across Aotearoa New Zealand.